World Journal of Urology

, Volume 1, Issue 1, pp 49–54 | Cite as

The clinical significance of steroid hormone measurements in the management of patients with prostatic cancer

  • R. Ghanadian
  • C. M. Puah


In a study involving 174 patients with proven carcinoma of the prostate the significance of steroid measurements in circulating blood, prostatic tissues and urine in relation to clinical management of patients was evaluated and the following findings were obtained: 1. Despite certain differences in the serum level of individual androgens between normal and malignant patients, single measurements of androgens does not provide a reliable index for differentiating the normal subjects from patients with carcinoma of the prostate. However, the ratio of testosterone (T) to either 5α-dihydrotestosterone (DHT) or 5α-androstane-3α, 17β-diol (diol) can provide a better discriminant. 2. Assessment of changes in serum T and DHT following endocrine therapy of 158 patients with carcinoma of the prostate showed that with the exception of radiotherapy a highly significant suppression of these androgens were found following orchidectomy, treatment with diethylstilboestrol (DES), estramustinephosphate (Estracyt) and cyproterone acetate. The latter compound produced the least suppression of T compared to the other endocrine modalities. Estracyt produced similar degrees of suppression of DHT as Cyproterone acetate, but less than either orchidectomy or DES. 3. The measurement of steroids in prostatic tissues provides a more reliable index for separating malignant from benign hypertrophied tissues. Androstenedione, oestradiol-17β and T were found to be significantly higher in malignant prostates, whilst DHT was higher in benign hypertrophied tissues. 4. Urinary measurements of unconjugated steroids proved to be the least effective means in assessing the endocrine status in patients with malignant prostates.


Testosterone Androgen Reliable Index Prostatic Tissue Androstenedione 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abraham GE (1974) Radioimmunoassay of steroids in biological materials. Acta Endocrinol [Suppl 183] 75:7Google Scholar
  2. 2.
    Bartsch, W, Horst HJ, Becker, H, Nehse G (1977) Sex hormone binding globulin binding capacity, testosterone, 5α-dihydrotestosterone oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol 85:650Google Scholar
  3. 3.
    Chamberlain J, Jagarinec N, Ofner P (1966) Catabolism of (4-14C) testosterone by subcellular fractions of human prostate. Biochem J 99:610Google Scholar
  4. 4.
    Chung LWK, Coffey DS (1978) Androgen glucuronide. II. Differences in its formation by human normal and benign hyperplastic prostates. Invest Urol 15:385Google Scholar
  5. 5.
    Farnsworth WE (1966) Metabolism of 19-nortestosterone by human prostate. Steroids 8:825Google Scholar
  6. 6.
    Gandy HM, Peterson RE (1968) Measurements of testosterone and 17-ketosteroids in plasma by the double isotope dilution derivative technique. J Clin Endocrinol Metab 28:949Google Scholar
  7. 7.
    Geller J, Albert J, Lopez D, Geller S, Niwayama A (1976) Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J Clin Endocrinol Metab 43:686Google Scholar
  8. 8.
    Ghanadian R, Lewis JG, Chisholm GD (1975) Serum testosterone and dihydrotestosterone changes with age in rat. Steroids 25:753Google Scholar
  9. 9.
    Ghanadian R, Smith CB, Williams G, Chisholm GD (1977) The effect of antiandrogens and stilboestrol on the cytosol receptor in rat prostate. Br J Urol 49:695Google Scholar
  10. 10.
    Ghanadian R, Puah CM, O'Donoghue EPN (1979) Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39:696Google Scholar
  11. 11.
    Ghanadian R, Masters JRW, Smith CB (1981) Altered androgen metabolism in carcinoma of the prostate. Eur Urol 7:169Google Scholar
  12. 12.
    Ghanadian R, Puah CM (1981) Age-related changes of serum 5α-androstane-3α,17β-diol in normal men. Gerontology 27:281Google Scholar
  13. 13.
    Ghanadian R, Puah CM (1981) Relationships between oestradiol-17β, testosterone, dihydrotestosterone and 5α-androstane-3α,17β-diol in human benign hypertrophy and carcinoma of the prostate. J Endocrinol 88:255Google Scholar
  14. 14.
    Ghanadian R (1982) Hormonal environment of the normal prostate. In: Ghanadian R (ed) The endocrinology of prostate tumours. MTP Press, Lancaster, p 35Google Scholar
  15. 15.
    Ghanadian R (1982) Hormonal control and rationale for endocrine therapy for prostatic tumours. In: Ghanadian R (ed) The endocrinology of prostate tumours. MTP Press, Lancaster, p 59Google Scholar
  16. 16.
    Habib FK, Lee IR, Stitch SR, Smith PH (1976) Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol 71:99Google Scholar
  17. 17.
    Hammond GL, Kontturi M, Vihko P, Vihko R (1978) Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 9:113Google Scholar
  18. 18.
    Harper ME, Peeling WB, Cowley T, Brownsey BG, Phillips MEA, Groom G, Fahmy DR, Griffiths K (1976) Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma before and during oestrogen therapy. Acta Endocrinol 81:409Google Scholar
  19. 19.
    Ito I, Horton R (1971) The source of plasma dihydrotestosterone in man. J Clin Invest 50:1621Google Scholar
  20. 20.
    James VHT, Braunsberg H, Rippon AE, Andino N, Parker V (1977) Measurement of androgens in biological fluids. In: Martini L, Motta M (eds). Raven Press, New York, p 22Google Scholar
  21. 21.
    Jonsson G, Olsson AM, Luttrop W, Cekan Z, Purvis K, Diczfalusy E (1975) Treatment of prostatic carcinoma with various types of estrogen derivatives. Vitam Horm 33:351Google Scholar
  22. 22.
    Kjeld, JM, Puah CM, Joplin GF (1977) Measurement of unconjugated testosterone, 5α-dihydrotestosterone and oestradiol in human urine. Clin Chim Acta 80:271Google Scholar
  23. 23.
    Mahoudeau JA, Bardin CW, Lipsett MB (1971) The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5α-androstanediols. J Clin Invest 50:1338Google Scholar
  24. 24.
    Morfin RF, Leave I, Charles JF, Cavazos LF, Ofner P, Floch HH (1977) Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39:1517Google Scholar
  25. 25.
    Ofner P, Morfin RF, Vena RL, Aliapoulis MA (1970) In some aspects of the aetiology and biochemistry of prostatic cancer. In: Griffiths K, Pierrepoint CG (eds) Proceedings of the Third Tenovus Workshop. Alpha Omega Alpha Publ, Cardiff, p 55Google Scholar
  26. 26.
    Pazzagli M, Borelli D, Forti G, Serio M (1974) Dihydrotestosterone in human spermatic venous plasma. Acta Endocrinol 76:388Google Scholar
  27. 27.
    Puah CM, Williams G, Ghanadian R (1982) Urinary unconjugated 5α-androstane-3α,17β-diol in patients with prostatic tumours. Urol Res 10:81Google Scholar
  28. 28.
    Rao PN, Khan AH, Moore PH (1977) Synthesis of new steroid haptens for radioimmunoassay. III. 15β-carboxyethylmercapto-steroidbovine serum albumin conjugated specific antisera for radioimmunoassay of 5α-dihydrotestosterone 5β-androstane-3α, 17β-diol and 5α-androstane-3α,17β-diol. Steroids 29:171Google Scholar
  29. 29.
    Schweikert HU (1979) Conversion of androstenedione to estrone in human fibroblasts cultured from prostate, genital and nongenital skin. Horm Metab Res 11:635Google Scholar
  30. 30.
    Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49:1737Google Scholar
  31. 31.
    Smith CB, Ghanadian R, Chisholm GD (1978) Inhibition of the nuclear dihydrotestosterone receptor complex from rat ventral prostate by antiandrogens and stilboestrol. Mol Cell Endocrinol 10:13Google Scholar
  32. 32.
    Tremblay RR, Kowarski A, Park IJ, Migeon CJ (1972) Blood production rate of dihydrotestosterone in the syndrome of male pseudohermaphroditism with testicular feminization. J Clin Endocrinol Metab 35:101Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • R. Ghanadian
    • 1
    • 2
  • C. M. Puah
    • 1
    • 2
  1. 1.Prostate Research LaboratoryRoyal Postgraduate Medical School, Hammersmith HospitalLondonUK
  2. 2.Institute of UrologyUniversity of LondonLondonUK

Personalised recommendations